Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
Nivolumab, Ipilimumab, Rp2
Metastatic Uveal Melanoma
Phase II/III
Recruiting
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Aug 29, 2024
―
Pembrolizumab, Nivolumab, Nivolumab + Relatlimab, Vusolimogene Oderparepvec, Single-Agent Chemotherapy
Advanced Melanoma
Phase III
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Jan 29, 2024
―
Bevacizumab, Atezolizumab, Rp2, Rp3
Refractory Metastatic Colorectal Cancer, Pmmr, Mss
Phase II
Active Not Recruiting
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Feb 08, 2023
―
Nivolumab, Rp3, Ccrt(Concurrent Chemoradiation Therapy), Carboplatin And Paclitaxel
Squamous Cell Carcinoma Of Head And Neck, Locally Advanced Head And Neck Squamous Cell Carcinoma, Recurrent Head And Neck Squamous Cell Carcinoma
Phase II
Withdrawn
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Feb 08, 2023
―
Bevacizumab, Durvalumab, Atezolizumab, Rp2
Hepatocellular Carcinoma, Biliary Tract Cancer
Phase II
Recruiting
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Feb 08, 2023
―
Nivolumab, Rp3
Advanced Solid Tumor
Phase I
Active Not Recruiting
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Jan 25, 2021
―
Rp1, Intra-Tumoral Injection, Oncolytic Virus
Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
Phase I/II
Recruiting
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
Apr 14, 2020
―
Nivolumab, Rp2
Cancer
Phase I
Recruiting
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Mar 17, 2020
―
Nivolumab, Rp1
Cancer, Nsclc, Cutaneous Melanoma, Melanoma (Skin), Microsatellite Instability, Mismatch Repair Deficiency, Non-Melanoma Skin Cancer
Phase II
Recruiting
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Dec 05, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Replimune Group Inc (REPL) have in its pipeline
REPL is currently developing the following drugs: Nivolumab, Ipilimumab, Rp2, Pembrolizumab, Nivolumab, Nivolumab + Relatlimab, Vusolimogene Oderparepvec, Single-Agent Chemotherapy, Bevacizumab, Atezolizumab, Rp2, Rp3. These drug candidates are in various stages of clinical development as the company works toward FDA approval.